CClinicalTrials.gg
Not yet recruitingNCT07044882Updated Jul 1, 2025

Hydrodynamic Piezoelectric Technique in Internal Sinus Lift

An interventional study of conventional osteotome technique and Hydrodynamic Piezoelectric technique in Maxillary Sinus Lift and Osteotome, sponsored by Hams Hamed Abdelrahman. Not yet recruiting at 1 site in Lebanon. Open to participants aged 30 Years to 50 Years. Per ClinicalTrials.gov, last updated 2025-07-01.

Sponsored by Hams Hamed Abdelrahman · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
22
Allocation
Randomized
Ages
30 Years to 50 Years
Sex
All
01

Study summary

Background: The use of hydrodynamic piezoelectric techniques for trans crestal / internal sinus lift with simultaneous implant placement has gained popularity as a safe and minimally invasive technique for managing the posterior edentulous maxilla, particularly in cases with sinus pneumatization. This method offers a controlled elevation of the Schneiderian membrane while reducing the risk of perforation compared to conventional techniques. Additionally, it minimizes postoperative discomfort and oedema, leading to better acceptance and satisfaction by the patients. In contrast to traditional osteotome tapping procedures, the hydrodynamic piezoelectric technique enhances surgical outcomes while preserving vital anatomical structures, making it a superior alternative in implant dentistry. This study aims to evaluate the use of the hydrodynamic piezoelectric technique in internal sinus lifting with simultaneous implant placement in comparison to the conventional osteotome technique.

02

Conditions studied

  • Maxillary Sinus Lift
  • Osteotome
03

Who can participate

Ages eligible
30 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  • Patients with edentulous free end or bounded posterior maxilla that require implant supported restoration.
  • Patients indicated to internal sinus lifting, where insufficient residual alveolar bone height from the alveolar crest to the floor of the maxillary sinus is found.
  • Patients with residual alveolar bone height that ranges from 5-7 mm according to the tomographic radiographic examination.
  • A good standard of oral hygiene.

Exclusion criteria:

  • Patients with residual alveolar bone height less than 5 mm according to the tomographic radiographic examination.
  • Patients with residual alveolar bone height more than 8 mm according to the tomographic radiographic examination, which is not indicated to sinus lifting.
  • Patient with active sinus infection or sinus pathology.
  • History of Oral or intravenous bisphosphonate therapy or any treatments with other medications that may interfere with bone metabolism within the past 12 months.
  • Heavy smokers.
  • Medically compromised patients that are burdened with systemic conditions that contradicts implant placement and interfere with wound healing.

Exclusion Criteria:

-

04

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
22 participants (estimated)

Study arms

  • Active comparator
    conventional osteotome technique

    Procedure: conventional osteotome technique

  • Experimental
    osteotome with hydrodynamic piezoelectric

    Procedure: Hydrodynamic Piezoelectric technique

Interventions

  • Procedureconventional osteotome technique

    Patients indicated for internal sinus lifting with simultaneous implant placement, where sinus elevation is conducted with regular manual osteotomes.

    Also known as: Control group

  • ProcedureHydrodynamic Piezoelectric technique

    Patients indicated for internal sinus lifting with simultaneous implant placement, where sinus elevation is conducted with Hydrodynamic Piezoelectric technique.

05

What researchers measure

Primary outcomes

  1. Change in pain scores

    Pain will be evaluated, using visual analogue scale (VAS) as follows: (0-1= None, 2-4= Mild, 5-7= Moderate, 8-10= Severe).

    Time frame: at 7, 14, and 21 days

  2. Change in wound healing

    The wound healing will be assessed based on the Modified Healing Index. The Wound Healing Index (WHI) evaluates preimplant soft tissue wound healing with scores from 1 to 3. On this scale, a score of 1 indicates ordinary healing with the absence of gingival edema, erythema, suppuration, patient discomfort, and flap dehiscence. A score of 2 indicates ordinary healing with slight gingival edema, erythema, patient discomfort, and flap dehiscence, but no suppuration and a score of 3 corresponds to poor wound healing with significant gingival edema, erythema, patient discomfort, suppuration, and flap dehiscence, or any suppuration

    Time frame: at 7, 14, and 21 days

  3. change in implant stability

    Implant Stability Quotient (ISQ) will be measured during the operative stage, while the secondary stability quotient will be measured 6-months post-operative during the prosthetic phase preparation using Ostell device.

    Time frame: baseline and 6 months

Secondary outcomes

  1. Change in Alveolar Process height gain

    The baseline residual alveolar bone height will be measured in the preoperative scan from the alveolar crest to the maxillary sinus floor. Immediate postoperative alveolar bone height will be measured to outline the effectiveness of sinus membrane elevation using CBCT

    Time frame: baseline and 6 months

06

Study locations

1 site
  • Faculty of Dentistry clinics, Beirut Arab University
    Beirut, Lebanon
    • Joseph Alkhoury, BDS · Contact
    • Joseph Alkhoury, BDS · Principal investigator
07

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT07044882
Lead sponsor
Hams Hamed Abdelrahman
Responsible party
Hams Hamed Abdelrahman (Lecturer of Dental Public Health and biostatistical consultanat, Alexandria University) — Sponsor-investigator
First posted
Jul 1, 2025
Start date
Oct 1, 2025 (estimated)
Primary completion
Apr 30, 2026 (estimated)
Completion
Apr 30, 2026 (estimated)
Last update
Jul 1, 2025

Study contacts

Joseph Alkhoury, BDS
Contact
Josephalkhoury@hotmail.com
+961 71 832 772

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion